Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms

Inclusion Criteria: * Adults patients aged over 18 years old at inclusion visit * Diagnosed as having OAG in one or both eyes * Who have used the previous preserved eye drops treatment for at least 4 weeks in one eye or both eyes * Experiencing pre-established ocular surface disease symptoms, as defined in the 2007 report of the International Dry Eye Workshop * Being scheduled by their ophthalmologist for a switch to preservative-free DTFC eye drops (as monotherapy or replacement of one preserved product of a combined therapy) at inclusion visit due to tolerability issues * Accepting to participate in the study and who has provided a written informed consent Exclusion Criteria: * Patients who had filtering or other ocular surgery within the 6 months preceding the inclusion visit * Who have already been treated with preservative-free DTFC * Whose visual acuity is importantly impaired by a severe ocular disease other than OAG, as assessed by the physician * Currently involved in a clinical trial or study cohort or pharmaco-epidemiology study or interventional study * With serious mental or physical disability which could interfere with a patient-reported assessment * Pregnant women.